Metzincins are key molecules in the degradation of the extracellular matrix and play an important role in cellular processes such as cell migration, adhesion, and cell fusion of malignant tumors, including cutaneous melanoma (CM). We hypothesized that genetic variants of the metzincin metallopeptidase family genes would be associated with CM-specific survival (CMSS). To test this hypothesis, we first performed Cox proportional hazards regression analysis to evaluate the associations between genetic variants of 75 metzincin metallopeptidase family genes and CMSS using the dataset from the genome-wide association study (GWAS) from The University of Texas MD Anderson Cancer Center (MDACC) which included 858 non-Hispanic white patients with CM, and then validated using the dataset from the Harvard GWAS study which had 409 non-Hispanic white patients with invasive CM. Four independent SNPs (MMP16 rs10090371 C>A, ADAMTS3 rs788935 T>C, TLL2 rs10882807 T>C and MMP9 rs3918251 A>G) were identified as predictors of CMSS, with a variant-allele attributed hazards ratio (HR) of 1.73 (1.32-2.29, 9.68E-05), 1.46 (1.15-1.85, 0.002), 1.68 (1.31-2.14, 3.32E-05) and 0.67 (0.51-0.87, 0.003), respectively, in the metaanalysis of these two GWAS studies. Combined analysis of risk genotypes of these four SNPs revealed a decreased CMSS in a dose-response manner as the number of risk Abbreviations: ADAMTS, a disintegrin-metalloproteinases with thrombospondin domains; ADAMTS3, ADAM metallopeptidase with thrombospondin type 1 motif 3; AUC, area under the curve; CI, confidence interval; CM, cutaneous melanoma; CMSS, cutaneous melanoma-specific survival; eQTL, expression quantitative trait loci; FPRP, false-positive report probability; GWAS, genome-wide association studies; HPFS, Health Professionals Follow-up Study; HR, hazards ratio; HWE, Hardy-Weinberg equilibrium; MAF, minor allelic frequency; MDACC, MD Anderson Cancer Center; MMP9, matrix metallopeptidase 9; MMP16, matrix metalloproteinase 16; NHS, Nurses' Health Study; SEER, surveillance, epidemiology, and end results; SNP, single-nucleotide polymorphisms; ROC, receiver operating characteristic; TLL2, tolloid-like protein 2; UV, ultraviolet.
genotypes increased (P trend < 0.001). An improvement was observed in the prediction model (area under the curve [AUC] = 81.4% vs. 78.6%), when these risk genotypes were added to the model containing non-genotyping variables. Our findings suggest that these genetic variants may be promising prognostic biomarkers for CMSS.
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| INTRODUCTION
Cutaneous melanoma (CM) is the fifth most common cancer in the United States, and its incidence rate is increasing by 3% annually. 1 Early diagnosis, immunomodulation (eg, anti-CTLA4), and targeted therapy (eg, BRAF and MEK inhibitors) have made breakthrough improvements in prognosis of advanced-stage CM patients. 2, 3 The 5-year (2006) (2007) (2008) (2009) (2010) (2011) (2012) survival rate of CM is estimated to be about 91.5% based on data from the surveillance, epidemiology, and end results (SEER) program.
CM is a complex disease that originates from melanocytes primarily found in the skin, risk of developing melanoma is influenced by both environmental and host factors. For example, ultraviolet (UV) exposure, an important environmental factor, has been recognized as an independent risk factor for CM, 4 which not only increases CM risk but also leads to tumor progression by affecting molecular signaling pathways and inhibiting immune reactions. 4 Host factors such as color of the skin, hair, and eyes, as well as genetic variants, have also been identified to be involved in CM development and progression. 4 In distinction to somatic mutations, germline variants with a low penetrance have a high frequency in the general population. In recent years, large-scale genome-wide association studies (GWASs) have identified a number of genetic variants as risk factors of many complex diseases, including CM. 5 Several single-nucleotide polymorphisms (SNPs) (such as, rs7526389, rs1539188, rs1049481, and rs2974755)
have been found to be independent predictors of CM prognosis. 6 However, GWASs may have identified many of the most statistically significant SNPs but also may have missed biologically functional and mechanistically important genetic variants that do not rank among the top SNPs. Recently, hypothesis-driven and pathway-based (or gene set-based) approaches have been effectively used to search for novel functional genetic variants that are associated with risk and prognosis of CM. 7 For example, PIWIL4 rs7933369 and rs508485 and DCP1A rs11551405 in the PIWI-piRNA pathway 8 and VDBP rs12512631 and RXRA rs7850212 in the vitamin D pathway 9 were found to be associated with CM prognosis. Investigations of functional genes and SNPs have provided additional evidence for the biological mechanisms underlying observed associations with CM prognosis. [10] [11] [12] Metzincin metallopeptidase family members, including matrixins, adamlysins, astacins, and pappalysins, are calcium-dependent zinc-containing endopepdidases that have proteolytic activities and play an important role in degradation of the extracellular matrix and some protein complexes. It has been reported that metzincin family genes play an important role in several cancer-progressionrelated processes, including cell migration, adhesion, and cell fusion of malignant diseases. [13] [14] [15] [16] [17] For example, matrix metalloproteinase 9
(MMP9) has been reported to be associated with cancer invasiveness and metastasis, and inhibitors against MMP9 represent a promising strategy for anti-melanoma therapy. 18 MMP12 expression has been reported to be increased in CM and related to tumor invasion and metastasis. 19 Moreover, high expression of the disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) was found to be related to melanoma metastasis. 20 The disintegrin-metalloproteinases with thrombospondin domains (ADAMTS) genes have been suggested to act as tumor suppressors in various cancers, including melanoma, and ADAMTS18 mutations can promote cell growth, migration, and metastasis of melanoma. 21 In addition, other metzincin family members, including astacins and pappalysins, have also been reported to be associated with tumorigenesis. 22, 23 To date, there are no reported studies using large-scale GWAS datasets to investigate the role of genetic variants of genes in the metzincin metallopeptidase family in melanoma survival. We hypothesize that genetic variants of the metzincin metallopeptidase family genes would be associated with CM-specific survival (CMSS).
| MATERIALS AND METHODS

| Study populations
with the MACH software based on the 1000 Genomes CEU population (March 2010 release). 26 The replication dataset included 409 non-Hispanic white patients with invasive CM in the two cohorts of Nurses' Health Study (NHS) and Health Professionals Follow-up Study (HPFS) from Harvard University, from which the information of age, sex, survival outcome, and genotype data were available. Genotyping was performed using the Illumina HumanHap610 array. Genome-wide imputation (imputation quality r 2 ≥ 0.8) was also performed using the MACH software based on the 1000 Genomes Project CEU population (March 2012 release). 27, 28 All individuals in the two datasets participated in these studies after providing a written informed consent under an Institutional
Review Board-approved protocol.
| Extraction of Genes and SNPs
The metzincin metallopeptidase family genes were selected from the 
| Statistical analysis
CMSS was considered the major end-point in in the present study, which was defined as the date from the diagnosis of malignant CM to the time of CM-related death or the time of the last follow-up. In the MDACC dataset, Cox proportional hazards regression analysis was performed with adjustment for age, sex, Breslow thickness, metastasis, ulceration, and mitotic rate (in an additive genetic model). We estimated the associations between SNPs in the metzincin metallopeptidase family genes and CMSS by calculating hazards ratio (HR) and its 95% confidence interval (CI) using the GenABEL package of R software. In the Harvard dataset, only age and sex were available for adjustment in the further Cox regression analysis. The false-positive report probability (FPRP) method with a cut-off value of 0.20 was used for multiple testing corrections. 29 FPRP was chosen because many imputed SNPs were in linkage disequilibrium (LD) among all the SNPs under investigation, and also it is calculated based on three factors, including the observed P-value, the prior probability of a true association of the tested genetic variant with a disease, and the statistical power of the test. In the present study, we assigned a prior probability of 0.10 to detect an HR of 2.0 for an association with variant genotypes or minor alleles of the SNPs with P ≤ 0.05. Then, we performed the multivariable stepwise Cox regression analysis including clinical variables and validated SNPs to select the independent representative SNPs in the MDACC dataset, and a meta-analysis was followed to combine the results between the MDACC and Harvard studies using PLINK 1.07. A fixed-effects model was used when no heterogeneity was found between two studies (Q-test P-value > 0.10 and I 2 < 50.0%); otherwise, a random-effects model was applied.
Kaplan-Meier curve and log-rank test were used to estimate the effects of risk genotypes on the cumulative probability of CMSS. 3 | RESULTS
| Gene and SNP extraction
Seventy-eight metzincin metallopeptidase family genes were selected from the HUGO gene family website (http://www.genenames.org/ cgi-bin/genefamilies/set/901) (Supplementary Table S1 ). Three pseudogenes (ADAM1B, ADAM24P and ADAM3B) were excluded from the gene list. After quality checks, 13 850 SNPs of 75 genes (ie, 2145 genotyped and 11 705 imputed SNPs) were extracted from the imputed MDACC GWAS dataset for further survival analysis.
| Associations between SNPs in the metzincin metallopeptidase family genes and CMSS in the MDACC dataset
We present the workflow of the analyses in Figure 1 . The basic characteristics of the MDACC and Harvard studies were described FIGURE 1 Research flowchart. SNP, single nucleotide polymorphism; CMSS, cutaneous melanoma-specific survival; FPRP, false-positive report probability; ROC, receiver operating characteristic; GWAS, genome-wide association study previously 24, 33 (Supplementary Table S2 ). We first performed Cox regression analysis with adjustment for age, sex, Breslow's thickness, metastasis, ulceration, and mitotic rate to evaluate associations between 13 850 SNPs of the metzincin metallopeptidase family genes and CMSS in single locus analysis. Among these SNPs, 570 SNPs were significantly associated with CMSS at P ≤ 0.05 in an additive genetic model. We then conducted multiple testing corrections for these 570
SNPs, and 322 SNPs with FPRP ≤ 0.20 were selected for validation in another independent dataset of the Harvard study (Supplementary Figure S1 ).
| Replication of the significant SNPs in the Harvard dataset
We validated the 322 SNPs by using the Harvard dataset. After Cox regression analysis with the adjustment for age and sex, eight SNPs remained significantly associated with CMSS at P ≤ 0.05 in an additive genetic model, including four SNPs (rs10090371, rs62525943, rs12674820, and rs7013966) in MMP16, two SNPs (rs788933 and rs788935) in ADAMTS3, one SNP (rs10882807) in TLL2, and one SNP (rs3918251) in MMP9 (Table 1) .
| Independent representative SNPs
We then performed a stepwise Cox regression analysis of selected clinical variables from the MDACC dataset plus the eight validated SNPs to identify independent predictors of CMSS from the eight validated SNPs (Table 2) 
| Survival analyses of the four independent SNPs and CMSS in MDACC and Harvard studies
We performed survival analysis with different genetic models for each independent SNP. As shown in Table 1 Table 3 .
| Combined genotype analyses of the four independent representative SNPs
We combined the risk genotypes of rs10090371 CA + AA, rs788935
TC + CC, rs10882807 TC + CC, and rs3918251 AA into a genetic score to assess the joint effect of the four independent SNPs on CMSS. We first combined groups of 0 and 1 risk genotypes into one group, because of their small number of subjects, and categorized all other patients into four groups (ie, 0-4 genetic scores, Table 3 ). Results suggested a risk-genotype dose-response in the effect on CMSS associated with the genetic score (P trend < 0.001 in both MDACC and
Harvard studies) after adjustments (Table 3 ). We further dichotomized the patients into a low-score risk group (0-2 risk genotypes) and a highscore risk group (3-4 risk genotypes). A similar result was observed that the high-score risk group had an increased risk of death with an HR of 3.55 (95%CI = 2.30-5.50, P < 0.001) in the MDACC study and an HR of 2.77 (95%CI = 1.56-4.90, P < 0.001) in the Harvard study, compared with the low-score risk group. Kaplan-Meier curves were also provided to illustrate the association between the number of risk genotypes and CMSS (Figure 2A-D 
| eQTL analyses
We further analyzed the associations between the four independent SNPs and levels of the corresponding gene mRNA expression (ie, expression quantitative trait loci analysis, eQTL analysis) using the data from the GTEx Portal (http://www.gtexportal.org/home/), which has the data for MMP16 rs10090371 in thyroid tissue, its moderate LD SNP rs12674820 in MMP16 (r 2 = 0.44) in adipose (subcutaneous) tissue and TLL2 rs10882807 in skin tissue. As shown in Supplementary Stepwise analysis included age, sex, regional/distant metastasis, Breslow thickness, ulceration, mitotic rate, and eight SNPs in four genes (rs10090371, rs62525943, rs12674820, and rs7013966 in MMP16; rs788933 and rs788935 in ADAMTS3; rs10882807 in TLL2; and rs3918251 in MMP9). b The "category/" was used as the reference. Figure S3A-C, MMP16 rs10090371 A, MMP16 rs12674820 G, and TLL2 rs10882807C alleles were associated with an increase in the corresponding gene mRNA expression levels with P values of 2.00E-05, 6.50E-10, and 1.30E-07, respectively. Because there were no expression data for the other two SNPs (ADAMTS3 rs788935 and MMP9 rs3918251) in the GTEx Portal, we further explored the potential function for these two SNPs by using the ENCODE project data. As shown in Supplementary Figure S3D -E, ADAMTS3 rs788935 is located at the intron region that shows H3K4Me1 enrichment, and MMP9 rs3918251 is also located at the intron region that is a DNase I hypersensitive area.
| DISCUSSION
Metzincins are considered key molecules in degradation of the extracellular matrix and play an important role in a variety of biological processes and pathological disorders, such as asthma, rheumatoid arthritis, and cancer, 34 including CM. The alterations of the metzincin metallopeptidase family genes in CM development and progression have been previously reported.
18-21
In the present study, we performed survival analysis for genetic variants in 75 metzincin metallopeptidase family genes and CMSS using the available MDACC and Harvard GWAS datasets. Four independent representative SNPs (MMP16 rs10090371 C>A, ADAMTS3 rs788935 T>C, TLL2 rs10882807 T>C, and MMP9 rs3918251 A>G) were identified as predictors of CMSS. Specifically, rs10090371A, rs788935C, and rs10882807C alleles were associated with a poor CMSS, and the rs3918251G allele was associated with a favorite outcome of CM. When we considered these four risk genotypes together, we also found that there was a risk-genotype dose-response in the effect on CMSS associated with the genetic score combining the four risk genotypes (rs10090371 CA+AA, rs788935 TC +CC, rs10882807 TC+CC, and rs3918251 AA). These four independent SNPs highlighted the roles of four genes (MMP16, ADAMTS3, TLL2, and MMP9) in CM patient survival.
MMP16, located at 8q21.3, encodes an enzyme called matrix metalloproteinase 16, which is a family member of matrix metalloproteinases (MMPs). Like the other MMPs, MMP16 is also associated with cancer cell proliferation, invasion, and metastasis. 35 It is suggested that MMP16 contributes to a poor prognosis in gastric cancer by promoting tumor cell proliferation and invasion. 35 Other studies have reported that MMP16 was associated with the migration and invasion of glioma and pancreatic cancer. 36, 37 Therefore, targeting MMP16 may be a feasible approach for inhibiting the progression of several cancers. Furthermore, MMP16 has been proposed to influence cell-cell adhesion and lymphatic invasion in melanoma. 38 Taken together, MMP16 may be considered to act as an oncogene and contribute to poor prognosis in multiple cancers, including CM. In the present study, the rs10090371 AA variant genotype was associated with an decreased CMSS, compared with the CC genotype, and the AA genotype was also associated with an increased MMP16 mRNA expression in thyroid tissue, although we did not have the data for skin or cutaneous tissue from the GTEx portal, another SNP rs12674820 in moderate LD (r 2 = 0.44) with rs10090371 was associated with increased MMP16 mRNA expression in subcutaneous tissue, which was consistent with the result of rs10090371 in thyroid tissue.
Therefore, it appears likely that SNPs in this region may influence gene function by mediating mRNA expression levels in multiple tissue types.
ADAMTS3, located at 4q13.3, encodes an enzyme called ADAM metallopeptidase with thrombospondin type 1 motif 3. As one of adamlysins family genes, ADAMTS3 also participates in various cellular processes, including extracellular matrix degradation, cleavage of proteoglycans, inhibition of angiogenesis, gonadal development, and organogenesis. 39 One study reported that ADAMTS3 was downregulated in breast cancer. 39 To date, there is no report about the role of ADAMTS3 in melanoma. In the present study, we found an association between the ADAMTS3 rs788935 and CM prognosis.
According to the ENCODE project data from UCSC, rs788935 is located at the intron region of ADAMTS3, which demonstrates considerable levels of H3K4Me1 enrichment that is accessible to transcription factors to enhance transcriptional activity. Therefore, it appears likely that SNPs in this region may influence gene expression by mediating the transcriptional activity.
TLL2, located at 10q24.1, encodes a protein called tolloid-like protein 2, which is an astacin-like zinc-dependent metalloprotease and is a subfamily member of the metzincin family. In the present study, this is the first report of an association between the TLL2 rs10882807 CC variant genotype and CM survival, and likely this genotype increases TLL2 mRNA expression in a variant allele doseresponse manner in skin tissue. Therefore, we propose that TLL2 may function as an oncogene to influence the melanoma progression. We acknowledge that additional functional studies are needed to validate our findings.
MMP9, located at 20q13.12, encodes an enzyme called matrix metallopeptidase 9 that also belongs to the MMPs family. MMP9 has been reported to be associated with the development and progression FIGURE 2 A-D, Kaplan-Meier survival curves for melanoma patients of combined analysis of four risk genotypes in MMP16, ADAMTS3, TLL2, and MMP9 in MDACC and Harvard studies. A, Combined analysis of risk genotypes (four groups) in MDACC study. B, Combined analysis of risk genotypes (two groups) in MDACC study. C, Combined analysis of risk genotypes (four groups) in Harvard study. D, Combined analysis of risk genotypes (two groups) in Harvard study. E-F, Receiver operating characteristic (ROC) curve and time-dependent area under the ROC curve (AUC) estimation for prediction of melanoma-specific survival using MDACC dataset. E, Ten-year melanoma-specific survival rate. F, Time-dependent AUC estimation, based on age, sex, Breslow thickness, regional/distant metastasis, ulceration, mitotic rate, and the risk genotypes of the four genes of many cancers. For example, one study reported that upregulating of MMP9 expression promoted hepatocellular carcinoma cell migration and invasion. 40 Another study suggested that increased MMP9 expression was associated with gastric cancer cell invasion. 41 In addition, MMP9 activity has been reported to be correlated with prognosis of other cancers, including cancers of the lung, 42 colorectum, 43 esophagus, 44 and breast. 45 Importantly, transcript levels of MMP9 were also observed to be increased in melanoma tumors, compared with that of melanocyte controls. 46 Additionally, it has been reported that MMP9 silencing inhibited mouse melanoma cell invasion and migration both in vitro and in vivo, suggesting that MMP9 might have promising applications for target therapy of CM. 47 Taken together, these data suggest that MMP9 acts as an oncogene contributing to poor prognosis across multiple cancers, including CM. In the present study, we found that the rs3918251 GG variant genotype was a protective factor for CMSS. According to the ENCODE project data from UCSC, rs3918251 is located at the DNase I hypersensitive area, where has lost the condensed structure, exposing the DNA and making it accessible to DNase I and transcription factors, plausibly influencing transcriptional activity. However, stronger functional evidence is needed to unravel the biological mechanisms underlying the observed association with CM survival.
There are some limitations in the present study. First, the MDACC study included clinical variables such as age, sex, primary tumor Breslow thickness, regional/distant metastasis, ulceration, and mitotic rate for adjustment, but the Harvard study included only age and sex.
Furthermore, additional potentially important clinical variables were not available for inclusion, such as performance status, nutritional status, tumor somatic mutation data, and details regarding treatment and response. Second, the study patients by design were all nonHispanic whites, therefore, our findings cannot be generalized to the general populations, and validations in other ethnic groups are needed.
Third, the GTEx portal and other biological function prediction websites are limited in their ability to definitively evaluate the function of the SNPs identified. More functional evidence is needed, and potential biological mechanisms should be explored by using the accessible melanoma tissues.
In conclusion, we evaluated associations between genetic variants of 75 metzincin metallopeptidase family genes and CMSS using MDACC and Harvard GWAS datasets. We identified MMP16 rs10090371 C>A, ADAMTS3 rs788935 T>C, TLL2 rs10882807 T>C and MMP9 rs3918251 A>G as possible predictors for CMSS.
Additional population replications from other ethnic groups and functional validation from mechanistic studies are needed to further validate our results. Once validated, our findings may provide promising prognostic biomarkers for personalized management and treatment of CM patients.
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